The clinical landscape of reproductive health is undergoing a significant shift as type 2 diabetes increasingly affects individuals of childbearing age, necessitating a radical overhaul of how medical systems approach preconception, gestational, and postpartum care. At the ENDO 2026 conference held in Chicago, Aoife M. Egan, MBBCh, PhD, an associate professor of medicine and consultant endocrinologist at the Mayo Clinic in Rochester, Minnesota, delivered a comprehensive presentation outlining the urgent need for individualized, patient-centered support. Her session, titled "Meet the Professor," highlighted the growing prevalence of type 2 diabetes among younger populations and the systemic barriers that prevent optimal outcomes for both mothers and infants. Dr. Egan’s findings underscore a critical juncture in endocrinology where the intersection of chronic metabolic disease and maternal-fetal medicine requires seamless, multidisciplinary coordination to mitigate long-term health risks.
The Epidemiological Shift: A Growing Crisis in Maternal Health
The rise of type 2 diabetes in younger demographics is no longer a peripheral concern but a central challenge for modern obstetrics and endocrinology. Historically, pregestational diabetes was dominated by type 1 cases; however, recent data indicates a dramatic reversal. Dr. Egan pointed to statistics from the United Kingdom’s national pregnancy audits to illustrate this trend, noting that the prevalence of type 2 diabetes has now far surpassed that of type 1 in pregnant populations. By 2021, approximately 10.9 out of every 1,000 births were complicated by preexisting diabetes mellitus (PDM), representing a 27% increase from 2016.
This surge is attributed to a confluence of factors, primarily the global obesity pandemic and shifting societal norms. As the average maternal age at childbirth continues to rise, the temporal window for developing chronic conditions like type 2 diabetes before conception widens. Furthermore, lifestyle factors—including reduced physical activity and a higher dietary reliance on ultra-processed foods—have accelerated the onset of insulin resistance in younger cohorts. Dr. Egan emphasized that type 2 diabetes in younger individuals often manifests as a more aggressive phenotype. This version of the disease tends to progress more rapidly toward complications such as retinopathy, nephropathy, and cardiovascular issues, making early intervention and rigorous glucose management during the reproductive years a matter of life-long health.
Understanding the Transgenerational Cycle
One of the most concerning aspects of the current diabetes epidemic is its potential for self-perpetuation across generations. Dr. Egan discussed emerging data regarding the "transgenerational effect," where the intrauterine environment significantly influences the future health of the offspring. Children born to mothers who experience any form of hyperglycemia during pregnancy—whether gestational or preexisting type 2 diabetes—are at a statistically higher risk of developing type 2 diabetes themselves later in life compared to those born to mothers with normal glucose levels.
This epigenetic programming creates a feedback loop: as the prevalence of diabetes in pregnancy increases, the baseline risk for the next generation rises, potentially leading to an exponential increase in metabolic disorders over the coming decades. Breaking this cycle requires more than just reactive treatment; it demands proactive metabolic optimization before a pregnancy even begins.
Addressing the Three Critical Practice Gaps
In her analysis, Dr. Egan identified three "yawning gaps" in current clinical practice that contribute to suboptimal outcomes. These gaps represent systemic failures in how healthcare is delivered to women with type 2 diabetes, ranging from the initial planning stages to the months following delivery.
1. The Preconception Counseling Void
The first major gap is the lack of formal preconception counseling. Statistics suggest that the majority of women living with type 2 diabetes do not receive specific medical guidance regarding pregnancy until they are already expecting. Without this early intervention, patients often enter pregnancy with suboptimal glycemic control (HbA1c levels), which significantly increases the risk of congenital anomalies, miscarriage, and stillbirth.
An ideal preconception model, as proposed by Dr. Egan, would involve screening for pregnancy intent at every clinical encounter. For those desiring pregnancy, a multidisciplinary team—comprising endocrinologists, maternal-fetal medicine specialists, dietitians, and diabetes educators—should work to stabilize blood sugar levels and manage comorbidities before conception. Conversely, for those not seeking pregnancy, robust contraceptive counseling is essential to prevent unplanned pregnancies under high-risk metabolic conditions.
2. The Pharmacotherapy Transition Dilemma
The second gap concerns the management of modern diabetes medications during the transition to pregnancy. The pharmaceutical landscape has been revolutionized by GLP-1 receptor agonists (such as semaglutide), DPP-4 inhibitors, and SGLT2 inhibitors. While these drugs are highly effective for weight loss and glucose control in non-pregnant adults, there is a profound lack of evidence regarding their safety for a developing fetus.
Currently, the standard of care involves transitioning patients to insulin—and occasionally metformin—once pregnancy is confirmed or during the preconception phase. However, without a controlled, pre-planned transition, patients often face a "rebound" effect where blood sugar levels spike and weight gain accelerates during the first trimester. Dr. Egan noted that making these therapeutic changes while a patient is also dealing with morning sickness and other early pregnancy symptoms is far from ideal. A controlled transition months before conception allows the patient and their care team to find the right insulin regimen without the added stress of active gestation.
3. Postpartum Care Fragmentation
The third gap is the fragmentation of care following delivery. During pregnancy, patients are often under intense medical supervision, but this support frequently evaporates after the baby is born. The transition from obstetric care back to primary care or endocrinology is where many patients are "lost to follow-up."
Dr. Egan described this as a "perfect storm." New mothers are often overwhelmed by the demands of a newborn, financial pressures, and the need to return to work, leading them to deprioritize their own metabolic health. This lack of follow-up is particularly dangerous for those who may have developed complications during pregnancy or who need to recalibrate their diabetes medications for the postpartum period.
Socioeconomic Barriers and Health Equity
The burden of type 2 diabetes in pregnancy does not fall equally across the population. Dr. Egan highlighted a "terrible irony": the individuals most affected by the disease are often those with the least access to the resources required to manage it. Socioeconomic challenges, low health literacy, and systemic biases against ethnic minorities create insurmountable barriers to care.
Public health initiatives aimed at reducing obesity and improving nutrition often fail to reach marginalized communities with the same efficacy as they do more affluent populations. Furthermore, the high cost of newer medications and the lack of insurance coverage for weight-loss interventions mean that those who could benefit most from modern therapies are frequently priced out of the market. Addressing the rise of type 2 diabetes in pregnancy, therefore, requires a commitment to health equity and the implementation of support systems that account for the social determinants of health.
Clinical Guidelines and the Path Forward
To address these challenges, the medical community is moving toward more standardized and evidence-based protocols. In July 2025, the Endocrine Society and the European Society of Endocrinology (ESE) released a joint clinical practice guideline titled "Preexisting Diabetes and Pregnancy." This document provides a roadmap for clinicians, synthesizing the latest evidence on medication safety and management strategies.
Dr. Egan, who has also co-authored a perspective piece for The Journal of Clinical Endocrinology & Metabolism, advocates for several practical changes in clinical settings:
- Integrated Electronic Medical Records (EMR): Ensuring that postpartum diabetes plans are clearly documented and that there is a warm hand-off between obstetricians and primary care providers.
- Virtual Care Integration: Utilizing telehealth to reach mothers who face geographic or logistical barriers to attending in-person postpartum appointments.
- Designated Navigators: Implementing healthcare workers or "patient navigators" to help high-risk individuals navigate the complexities of the healthcare system.
Conclusion: A Call to Action for Longitudinal Care
The overarching message of Dr. Egan’s presentation at ENDO 2026 was one of cautious optimism. While the statistics regarding type 2 diabetes in pregnancy are sobering, the evidence suggests that individualized, patient-centered care can profoundly improve outcomes. The challenge lies in restructuring healthcare delivery to ensure that this care is accessible to all, regardless of their socioeconomic background.
For clinicians, the mission is to close the gaps in preconception and postpartum care through better communication and multidisciplinary collaboration. For patients, the goal is to provide a supportive environment where a diagnosis of type 2 diabetes does not preclude the possibility of a healthy, positive pregnancy experience. By addressing the "aggressive phenotype" of early-onset diabetes and the systemic failures that hinder treatment, the medical community can work toward a future where both mother and child are shielded from the long-term consequences of this metabolic crisis. Dr. Egan’s work serves as a vital reminder that in the realm of endocrinology, effective care must be as continuous and dynamic as the lives of the patients it serves.
